Navigation Links
Erste Klage gegen Nobelpreis-Organisation wegen Verleumdung und unlauterem Wettbewerb eingereicht
Date:12/7/2012

LOS ANGELES, 7. Dez. 2012 /PRNewswire/ -- Dr. Rongxiang Xu, der Begründer der „Human Body Regenerative Restoration Science" (z. Dt.: Regenerative Wissenschaft zur Restaurierung des menschlichen Körpers) und ein bekannter Biowissenschaftler und Mediziner, hat heute Klage gegen die Nobelversammlung des Karolinska-Instituts (The Nobel Assembly at Karolinska Institutet) eingereicht – ein schwedisches Unternehmen, das auch als Nobelförsamlingen bekannt ist. Die Nobelversammlung des Karolinska-Instituts ist ein Gremium, das den Nobelpreis für Physiologie oder Medizin vergibt. Die Klage wegen Verleumdung und unlauterem Wettbewerb wurde vor dem Justizzentrum des Obersten Gerichtshof des Bundesstaats Kalifornien in Orange County eingereicht.

Als einer der führenden Wissenschaftler der Welt entdeckte Dr. Xu im Jahre 1984 die Existenz „regenerativer Zellen", die erst später – im Zuge seiner Studie zur Verbrennungsmedizin aus dem Jahr 2000, die 20 Millionen Brandopfer aus 73 Ländern geholfen hat – als Keratin-19-positive Stammzellen identifiziert wurden (US-Patent: 6991813B2). Nun behauptet der Kläger, dass sein guter Ruf in der Branche aufgrund einer Erklärung des Beklagten, der Nobelversammlung, gelitten habe und dass die Versammlung Dr. Xu mit ihrer Vorgehensweise unmittelbar geschadet habe. In der Klageschrift wird behauptet, die Nobelversammlung habe mit ihren Meldungen zum Nobelpreis in praktisch jeder bedeutenden Nachrichtenagentur und Publikation der Welt erfolgreich für großes Medieninteresse gesorgt, wodurch belegt ist, dass sie die individuelle Wahrnehmung durch Falschdarstellungen beeinflussen kann.

„Mein wichtigster Beweggrund für die Einreichung dieser Klage war, die falschen und irreführenden Erklärungen der Akademie bezüglich der Erhaltung der Menschheit und zukünftiger Generationen richtigzustellen. Die biowissenschaftliche Forsch
'/>"/>

SOURCE Mebo International
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... BOSTON, MA (PRWEB) March 03, 2015 ... Print Supply Chain, today announced the expansion of its ... quality, color-matched print to 850 the world’s largest cities ... Supply Chain extends to 137 countries providing global enterprises ... the print procurement process from online order to real-world ...
(Date:3/3/2015)... 2015  Thingee Corporation, a software development company for ... entitled, "Technology Adoption: Making Reps, Lives Easier" during the ... Technology ,  in Deerfield Beach, Florida ... Audiences looking to learn how technology can help them ... in the audience for the Thingee presentation. ...
(Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the Company and ... 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy ... Santa Ana division (the "Bankruptcy Court") on ... to be jointly administered. The Company will evaluate ... for all or substantially all of its assets to a ...
Breaking Biology Technology:Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Thingee to present at 11th Annual Synergistix Users Conference 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4
... NATICK, Mass., Nov. 9, 2010 Boston Scientific Corporation ... implantation of its Vercise™ Deep Brain Stimulation (DBS) System ... a multi-center, prospective trial designed to examine the improvement ... with the Vercise DBS System for the treatment of ...
... Life Sciences Holdings, Inc. (OTC Bulletin Board: ... discovery, development and commercialization of novel drugs in the ... announced that it has submitted a full proposal to ... under BAA-NIAID-DMID-NIHAI2010097 Development Of Therapeutics For Biodefense . ...
... Professor Andre Geim, who along with his colleague Professor ... the world,s thinnest material, has now modified it ... to Teflon. Fluorographene is fully-fluorinated graphene and is ... including chemical inertness and thermal stability. The ...
Cached Biology Technology:Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 2Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 3Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 4Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 2Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 3Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 4Graphene gets a Teflon makeover 2Graphene gets a Teflon makeover 3
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... to a report issued last week by UNAIDS, access ... worldwide. But Dr. Groesbeck Parham, gynecologic oncologist and ... Center for Infectious Disease Research in Zambia (CIDRZ) warns ... dying of cervical cancer unless they have access to ...
... at The University of Manchester have developed a new x-ray ... and human cancers more effectively. Professor Robert Cernik and ... colour 3D X-ray system that allows material at each point ... work is reported in the latest issue of The Journal ...
... for commercial genetic testing is on the rise and ... (MGH) physician. In the December issue of Obstetrics ... testing is poorly regulated and may present potential pitfalls ... that are being offered have no proven clinical validity ...
Cached Biology News:Women with AIDS face cervical cancer threat 2New X-ray technique targets terrorists and tumors 2Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Fibulin-2 (D-15)...
Biology Products: